mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0...
Saved in:
| Published in | Cell Vol. 185; no. 9; pp. 1556 - 1571.e18 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
28.04.2022
Cell Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%–80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.
[Display omitted]
•mRNA-1273 prime induces cross-reactive B cells to Omicron and ancestral strains•Boosting with mRNA-1273 or mRNA-Omicron enhances neutralization of Omicron•Either boost expands B cells cross-reactive to Omicron and ancestral strains•mRNA-1273 or mRNA-Omicron boost is protective against Omicron replication in the lungs
Boosting previously vaccinated nonhuman primates with either the mRNA-1273 or mRNA-Omicron vaccine expands cross-reactive memory B cells and elicits similar levels of protection upon challenge with SARS-CoV-2 Omicron. |
|---|---|
| AbstractList | SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID
50
at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%–80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.
Boosting previously vaccinated nonhuman primates with either the mRNA-1273 or mRNA-Omicron vaccine expands cross-reactive memory B cells and elicits similar levels of protection upon challenge with SARS-CoV-2 Omicron. SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost. SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%–80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost. [Display omitted] •mRNA-1273 prime induces cross-reactive B cells to Omicron and ancestral strains•Boosting with mRNA-1273 or mRNA-Omicron enhances neutralization of Omicron•Either boost expands B cells cross-reactive to Omicron and ancestral strains•mRNA-1273 or mRNA-Omicron boost is protective against Omicron replication in the lungs Boosting previously vaccinated nonhuman primates with either the mRNA-1273 or mRNA-Omicron vaccine expands cross-reactive memory B cells and elicits similar levels of protection upon challenge with SARS-CoV-2 Omicron. SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID₅₀ at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%–80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost. SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost. |
| Author | Douek, Daniel C. Shi, Wei Corbett, Kizzmekia S. Godbole, Sucheta Todd, John-Paul M. Henry, Amy R. Lai, Yen-Ting Naisan, Mursal Bock, Kevin W. Stewart-Jones, Guillaume Dodson, Alan Carfi, Andrea Flebbe, Dillon R. Van Ry, Alex Roederer, Mario McCormick, Lauren Minai, Mahnaz Wagner, Danielle A. Ellis, Madison McDermott, Adrian B. Patel, Mit Dulan, Caitlyn N.M. McCarthy, Elizabeth Foster, Stephanie L. O’Dell, Sijy Harris, Darcy R. Foulds, Kathryn E. Laboune, Farida Edara, Venkata-Viswanadh Steingrebe, Katelyn Cordon, Jamilet Cook, Anthony Olia, Adam S. Lewis, Mark G. Chuang, Gwo-Yu Werner, Anne P. Willis, Jacquelyn Nurmukhambetova, Saule T. Amin, Shivani Lorang, Cynthia G. Yang, Eun Sung Suthar, Mehul S. Trost, Jessica Malinowski, Agata Zhang, Yi Lin, Bob C. Narvaez, Brandon Kwong, Peter D. Valentin, Daniel Renzi, Isabella Roberts-Torres, Jesmine Pessaint, Laurent Edwards, Darin K. Maldonado, Nahara Vargas Seder, Robert A. Teng, I-Ting Schmidt, Stephen D. Sullivan, Nancy J. Moliva, Juan I. Wu, Kai Flynn, Barbara J. Andrew, Shayne F. Wang, Lingshu Gagn |
| Author_xml | – sequence: 1 givenname: Matthew surname: Gagne fullname: Gagne, Matthew organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 2 givenname: Juan I. surname: Moliva fullname: Moliva, Juan I. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 3 givenname: Kathryn E. surname: Foulds fullname: Foulds, Kathryn E. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 4 givenname: Shayne F. surname: Andrew fullname: Andrew, Shayne F. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 5 givenname: Barbara J. surname: Flynn fullname: Flynn, Barbara J. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 6 givenname: Anne P. surname: Werner fullname: Werner, Anne P. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 7 givenname: Danielle A. surname: Wagner fullname: Wagner, Danielle A. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 8 givenname: I-Ting surname: Teng fullname: Teng, I-Ting organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 9 givenname: Bob C. surname: Lin fullname: Lin, Bob C. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 10 givenname: Christopher surname: Moore fullname: Moore, Christopher organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 11 givenname: Nazaire surname: Jean-Baptiste fullname: Jean-Baptiste, Nazaire organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 12 givenname: Robin surname: Carroll fullname: Carroll, Robin organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 13 givenname: Stephanie L. surname: Foster fullname: Foster, Stephanie L. organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 14 givenname: Mit surname: Patel fullname: Patel, Mit organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 15 givenname: Madison surname: Ellis fullname: Ellis, Madison organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 16 givenname: Venkata-Viswanadh surname: Edara fullname: Edara, Venkata-Viswanadh organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 17 givenname: Nahara Vargas surname: Maldonado fullname: Maldonado, Nahara Vargas organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 18 givenname: Mahnaz surname: Minai fullname: Minai, Mahnaz organization: Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA – sequence: 19 givenname: Lauren surname: McCormick fullname: McCormick, Lauren organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 20 givenname: Christopher Cole surname: Honeycutt fullname: Honeycutt, Christopher Cole organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 21 givenname: Bianca M. surname: Nagata fullname: Nagata, Bianca M. organization: Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA – sequence: 22 givenname: Kevin W. surname: Bock fullname: Bock, Kevin W. organization: Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA – sequence: 23 givenname: Caitlyn N.M. surname: Dulan fullname: Dulan, Caitlyn N.M. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 24 givenname: Jamilet surname: Cordon fullname: Cordon, Jamilet organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 25 givenname: Dillon R. surname: Flebbe fullname: Flebbe, Dillon R. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 26 givenname: John-Paul M. surname: Todd fullname: Todd, John-Paul M. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 27 givenname: Elizabeth surname: McCarthy fullname: McCarthy, Elizabeth organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 28 givenname: Laurent surname: Pessaint fullname: Pessaint, Laurent organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 29 givenname: Alex surname: Van Ry fullname: Van Ry, Alex organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 30 givenname: Brandon surname: Narvaez fullname: Narvaez, Brandon organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 31 givenname: Daniel surname: Valentin fullname: Valentin, Daniel organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 32 givenname: Anthony surname: Cook fullname: Cook, Anthony organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 33 givenname: Alan surname: Dodson fullname: Dodson, Alan organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 34 givenname: Katelyn surname: Steingrebe fullname: Steingrebe, Katelyn organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 35 givenname: Saule T. surname: Nurmukhambetova fullname: Nurmukhambetova, Saule T. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 36 givenname: Sucheta surname: Godbole fullname: Godbole, Sucheta organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 37 givenname: Amy R. surname: Henry fullname: Henry, Amy R. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 38 givenname: Farida surname: Laboune fullname: Laboune, Farida organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 39 givenname: Jesmine surname: Roberts-Torres fullname: Roberts-Torres, Jesmine organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 40 givenname: Cynthia G. surname: Lorang fullname: Lorang, Cynthia G. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 41 givenname: Shivani surname: Amin fullname: Amin, Shivani organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 42 givenname: Jessica surname: Trost fullname: Trost, Jessica organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 43 givenname: Mursal surname: Naisan fullname: Naisan, Mursal organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 44 givenname: Manjula surname: Basappa fullname: Basappa, Manjula organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 45 givenname: Jacquelyn surname: Willis fullname: Willis, Jacquelyn organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 46 givenname: Lingshu surname: Wang fullname: Wang, Lingshu organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 47 givenname: Wei surname: Shi fullname: Shi, Wei organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 48 givenname: Nicole A. surname: Doria-Rose fullname: Doria-Rose, Nicole A. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 49 givenname: Yi surname: Zhang fullname: Zhang, Yi organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 50 givenname: Eun Sung surname: Yang fullname: Yang, Eun Sung organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 51 givenname: Kwanyee surname: Leung fullname: Leung, Kwanyee organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 52 givenname: Sijy surname: O’Dell fullname: O’Dell, Sijy organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 53 givenname: Stephen D. surname: Schmidt fullname: Schmidt, Stephen D. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 54 givenname: Adam S. surname: Olia fullname: Olia, Adam S. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 55 givenname: Cuiping surname: Liu fullname: Liu, Cuiping organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 56 givenname: Darcy R. surname: Harris fullname: Harris, Darcy R. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 57 givenname: Gwo-Yu surname: Chuang fullname: Chuang, Gwo-Yu organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 58 givenname: Guillaume surname: Stewart-Jones fullname: Stewart-Jones, Guillaume organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 59 givenname: Isabella surname: Renzi fullname: Renzi, Isabella organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 60 givenname: Yen-Ting surname: Lai fullname: Lai, Yen-Ting organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 61 givenname: Agata surname: Malinowski fullname: Malinowski, Agata organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 62 givenname: Kai surname: Wu fullname: Wu, Kai organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 63 givenname: John R. surname: Mascola fullname: Mascola, John R. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 64 givenname: Andrea surname: Carfi fullname: Carfi, Andrea organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 65 givenname: Peter D. surname: Kwong fullname: Kwong, Peter D. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 66 givenname: Darin K. surname: Edwards fullname: Edwards, Darin K. organization: Moderna Inc., Cambridge, MA 02139, USA – sequence: 67 givenname: Mark G. surname: Lewis fullname: Lewis, Mark G. organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 68 givenname: Hanne surname: Andersen fullname: Andersen, Hanne organization: Bioqual, Inc., Rockville, MD 20850, USA – sequence: 69 givenname: Kizzmekia S. surname: Corbett fullname: Corbett, Kizzmekia S. organization: Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA – sequence: 70 givenname: Martha C. surname: Nason fullname: Nason, Martha C. organization: Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 71 givenname: Adrian B. surname: McDermott fullname: McDermott, Adrian B. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 72 givenname: Mehul S. surname: Suthar fullname: Suthar, Mehul S. organization: Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 73 givenname: Ian N. surname: Moore fullname: Moore, Ian N. organization: Division of Pathology, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA – sequence: 74 givenname: Mario surname: Roederer fullname: Roederer, Mario organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 75 givenname: Nancy J. surname: Sullivan fullname: Sullivan, Nancy J. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 76 givenname: Daniel C. surname: Douek fullname: Douek, Daniel C. email: ddouek@mail.nih.gov organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 77 givenname: Robert A. orcidid: 0000-0003-3133-0849 surname: Seder fullname: Seder, Robert A. email: rseder@mail.nih.gov organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35447072$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUl1rFDEUDVKx2-of8EHy6ENnvfmaDxChlvoBxYLoc8hk7tQsM8mYzC7qb-iPNuNuRX0oQiCEnHPu4Zx7Qo588EjIUwZrBqx8sVlbHIY1B87XIPKpH5AVg6YqJKv4EVkBNLyoy0oek5OUNgBQK6UekWOhpKyg4ityO378cF4wXgkaIv31uB6djcHTNoQ0U-fpzljrvJmxo6Ox5usWE8XBWTcnmtzoBhPpa7p4ofhtMj654M-ox-0czeB-OH9DI6Yp-ITpjBrf0SmGGe2ccbSPYaSHkY_Jw94MCZ8c7lPy-c3lp4t3xdX12_cX51eFVUrOBbYAFgxva2UVB9m2LSjRq76TrbSlrVXXcw4C-6qxDBSrbW-tqCRjthc9F6fk1V532rYjdhb94lRP0Y0mftfBOP33j3df9E3Y6bqRVSNlFnh-EIhhiWPWo0tLAMZj2CbNyxKaWjQN_w-okryRTNYZ-uxPW7_93LWVAfUekMNKKWKvcwdmiTG7dINmoJfF0Bu9DNDLYmgQ-Sza_B_qnfq9pJd7EuYydg6jTtaht9i5mOvTXXD30X8CaTnT8Q |
| CitedBy_id | crossref_primary_10_1038_s41467_023_43420_x crossref_primary_10_3389_fimmu_2025_1524477 crossref_primary_10_3390_v15030763 crossref_primary_10_3389_fimmu_2022_897879 crossref_primary_10_1016_j_biopha_2025_117936 crossref_primary_10_1038_s41590_024_01951_5 crossref_primary_10_3390_vaccines11040875 crossref_primary_10_1093_infdis_jiac356 crossref_primary_10_1093_intimm_dxac055 crossref_primary_10_1038_s41541_023_00645_7 crossref_primary_10_3389_fimmu_2022_1058748 crossref_primary_10_3390_vaccines11030672 crossref_primary_10_1038_s41577_022_00771_8 crossref_primary_10_3389_fimmu_2023_1114396 crossref_primary_10_3389_fimmu_2024_1345499 crossref_primary_10_1038_s41586_023_06951_3 crossref_primary_10_3390_vaccines11050963 crossref_primary_10_1038_s42003_023_04589_5 crossref_primary_10_1038_s41541_023_00622_0 crossref_primary_10_3390_v14092009 crossref_primary_10_1016_j_epidem_2024_100762 crossref_primary_10_1126_science_adc9127 crossref_primary_10_3389_fimmu_2024_1339660 crossref_primary_10_1038_s41467_022_33985_4 crossref_primary_10_1126_sciimmunol_adg0033 crossref_primary_10_1038_s41392_022_00997_x crossref_primary_10_1038_s41467_022_35456_2 crossref_primary_10_1136_bmjgh_2023_011879 crossref_primary_10_3389_fimmu_2023_1086035 crossref_primary_10_3390_v15010101 crossref_primary_10_1016_j_isci_2022_105465 crossref_primary_10_1038_s41577_022_00722_3 crossref_primary_10_1126_scitranslmed_ado9026 crossref_primary_10_3390_vaccines11121798 crossref_primary_10_1038_s41467_023_44265_0 crossref_primary_10_3389_fimmu_2024_1328905 crossref_primary_10_1038_s41392_022_00980_6 crossref_primary_10_1016_j_immuni_2022_07_020 crossref_primary_10_1016_j_xcrm_2023_101084 crossref_primary_10_1038_s41467_024_47784_6 crossref_primary_10_1038_s41586_024_07539_1 crossref_primary_10_1126_science_abq0203 crossref_primary_10_1172_jci_insight_159944 crossref_primary_10_1038_s41467_022_30340_5 crossref_primary_10_1038_s41467_022_33209_9 crossref_primary_10_1371_journal_pcbi_1012215 crossref_primary_10_3389_fimmu_2022_985478 crossref_primary_10_3390_pharmaceutics15071969 crossref_primary_10_1002_biot_202400596 crossref_primary_10_1038_s41590_022_01248_5 crossref_primary_10_1016_j_ymthe_2023_09_002 crossref_primary_10_3390_v15040917 crossref_primary_10_1038_s41467_022_33549_6 crossref_primary_10_1128_mbio_02928_23 crossref_primary_10_3390_jcm11216272 crossref_primary_10_1016_j_vaccine_2025_126961 crossref_primary_10_1371_journal_ppat_1012456 crossref_primary_10_1038_s41541_022_00575_w crossref_primary_10_1021_acs_jproteome_2c00514 crossref_primary_10_1038_s41541_024_00806_2 crossref_primary_10_1080_14712598_2022_2137402 crossref_primary_10_1016_j_ijid_2022_07_038 crossref_primary_10_1038_s41541_024_00821_3 crossref_primary_10_3390_v14122646 crossref_primary_10_3390_vaccines10081223 crossref_primary_10_1126_sciimmunol_adg7015 crossref_primary_10_3390_ijms23137315 crossref_primary_10_1016_j_antiviral_2023_105556 crossref_primary_10_3390_vaccines11040832 crossref_primary_10_1038_s41392_025_02154_6 crossref_primary_10_1038_s41598_023_50822_w crossref_primary_10_1038_s41392_022_01166_w crossref_primary_10_3389_fimmu_2022_898520 crossref_primary_10_1038_s41422_022_00746_3 crossref_primary_10_1038_s41541_023_00640_y crossref_primary_10_1002_ctm2_923 crossref_primary_10_1002_btm2_10709 crossref_primary_10_3390_pathogens12050655 crossref_primary_10_1038_s41467_022_32527_2 crossref_primary_10_1080_22221751_2023_2179357 crossref_primary_10_1172_JCI164303 crossref_primary_10_1186_s12929_022_00853_8 crossref_primary_10_1016_j_biopha_2024_117187 crossref_primary_10_1002_jmv_28428 crossref_primary_10_1038_s41590_024_01776_2 crossref_primary_10_1126_sciadv_ade1860 crossref_primary_10_1002_mco2_539 crossref_primary_10_1080_14760584_2022_2077196 crossref_primary_10_1038_s41541_023_00633_x crossref_primary_10_1126_scitranslmed_abq1945 crossref_primary_10_3389_fimmu_2023_1050037 crossref_primary_10_1056_NEJMra2206573 crossref_primary_10_3390_v15030624 crossref_primary_10_1073_pnas_2311752120 crossref_primary_10_1128_cmr_00014_22 crossref_primary_10_1126_scitranslmed_abq4130 crossref_primary_10_1016_j_isci_2023_106694 crossref_primary_10_1016_j_chom_2022_10_012 crossref_primary_10_1038_s41467_023_37715_2 crossref_primary_10_1111_1751_7915_14064 crossref_primary_10_3389_fimmu_2024_1420304 crossref_primary_10_1080_21505594_2024_2316438 crossref_primary_10_1038_s41467_024_51046_w crossref_primary_10_1186_s41232_023_00255_9 crossref_primary_10_1016_j_celrep_2023_112167 crossref_primary_10_1016_j_ebiom_2022_104196 crossref_primary_10_1002_jmv_28163 crossref_primary_10_1016_j_chom_2023_07_004 crossref_primary_10_1016_j_immuni_2022_05_005 crossref_primary_10_1186_s12951_025_03200_9 crossref_primary_10_3390_v14112488 crossref_primary_10_1038_s41467_023_38457_x crossref_primary_10_1080_22221751_2023_2169198 crossref_primary_10_1002_cti2_1434 crossref_primary_10_3389_fmats_2022_1039247 crossref_primary_10_1126_science_abq1841 crossref_primary_10_1016_j_cell_2022_09_032 crossref_primary_10_1038_s41541_024_00982_1 crossref_primary_10_3390_vaccines10071070 crossref_primary_10_1093_infdis_jiac384 crossref_primary_10_1002_mco2_238 crossref_primary_10_1038_s41591_022_02031_7 crossref_primary_10_1002_jmv_27885 crossref_primary_10_1038_s41591_022_02092_8 crossref_primary_10_3389_fimmu_2023_1167214 crossref_primary_10_1016_S1473_3099_23_00119_6 crossref_primary_10_1038_s41392_022_01192_8 crossref_primary_10_1038_s41392_023_01579_1 crossref_primary_10_3389_fimmu_2022_1031254 |
| Cites_doi | 10.1038/s41591-021-01527-y 10.1016/j.cell.2021.01.050 10.1016/j.chom.2021.03.002 10.1038/s41586-022-04411-y 10.1056/NEJMc2115597 10.1002/cpim.116 10.1056/NEJMoa2109072 10.1016/j.jbc.2021.101127 10.1038/s41586-021-04387-1 10.1002/cyto.a.23670 10.1056/NEJMoa2106599 10.1126/science.abn7591 10.1126/science.1256427 10.1126/science.1175870 10.1016/j.cell.2021.12.033 10.1056/NEJMc2119912 10.1126/science.abj0299 10.1038/s41586-021-03777-9 10.1371/journal.pntd.0006862 10.1016/S0140-6736(22)00017-4 10.1126/science.abm3425 10.1016/j.cell.2020.04.011 10.1126/science.abl8912 10.1056/NEJMoa2114228 10.1038/s41590-021-01021-0 10.1126/science.1176676 10.1038/s41586-020-2196-x 10.1016/j.cell.2021.12.002 10.1056/NEJMoa2022483 10.1016/j.celrep.2020.108322 10.1126/science.aag1322 10.1016/j.immuni.2021.06.003 10.1038/s41586-020-2349-y 10.1073/pnas.1707304114 10.1001/jama.2022.0470 10.1038/s41577-022-00678-4 10.1016/S0140-6736(21)02249-2 10.1016/j.immuni.2021.06.018 10.3390/v14020294 10.1126/scitranslmed.abi4547 10.1056/NEJMoa2115926 10.1056/NEJMc2107799 10.1056/NEJMoa2024671 10.1126/science.abh1766 10.1038/s41423-022-00838-5 10.1073/pnas.93.21.11382 10.1038/s41586-021-03594-0 10.1016/j.omtn.2019.01.013 10.1016/j.xcrm.2022.100529 10.1038/s41586-022-04474-x 10.1016/j.cell.2021.12.032 10.1056/NEJMoa2034577 10.1038/s41591-021-01678-y 10.1126/science.abb2507 10.1056/NEJMc2119641 10.1016/0167-5699(94)90192-9 10.1128/mBio.02749-21 10.1016/j.ijid.2021.12.357 10.1016/j.chom.2021.03.009 10.1038/s41586-021-03207-w 10.1056/NEJMoa2101765 10.1073/pnas.1324197111 10.1001/jama.2021.24868 10.1056/NEJMoa2035389 10.1038/s41586-022-04441-6 10.4049/jimmunol.169.8.4298 |
| ContentType | Journal Article |
| Copyright | 2022 Published by Elsevier Inc. |
| Copyright_xml | – notice: 2022 – notice: Published by Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.cell.2022.03.038 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE AGRICOLA MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1097-4172 |
| EndPage | 1571.e18 |
| ExternalDocumentID | PMC8947944 35447072 10_1016_j_cell_2022_03_038 S0092867422003889 |
| Genre | Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIH HHS grantid: P51 OD011132 |
| GroupedDBID | --- --K -DZ -ET -~X 0R~ 0WA 1RT 1~5 29B 2FS 2WC 3EH 4.4 457 4G. 53G 5GY 5RE 62- 6J9 7-5 85S AACTN AAEDW AAFTH AAFWJ AAIAV AAKRW AAKUH AALRI AAUCE AAVLU AAXUO ABCQX ABJNI ABMAC ABMWF ABOCM ABVKL ACGFO ACGFS ACNCT ADBBV ADEZE ADJPV AEFWE AENEX AEXQZ AFTJW AGHSJ AGKMS AHHHB AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL CS3 DIK DU5 E3Z EBS F5P FCP FDB FIRID HH5 IH2 IHE IXB J1W JIG K-O KOO KQ8 L7B LX5 M3Z M41 N9A O-L O9- OK1 P2P RCE RNS ROL RPZ SCP SDG SDP SES SSZ TAE TN5 TR2 TWZ UKR UPT VQA WH7 WQ6 YZZ ZA5 ZCA .-4 .55 .GJ .HR 1CY 1VV 2KS 3O- 5VS 6TJ 9M8 AAEDT AAHBH AAIKJ AAMRU AAQFI AAQXK AAYJJ AAYWO AAYXX ABDGV ABDPE ABEFU ABWVN ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN ADXHL AETEA AEUPX AFPUW AGCQF AGHFR AGQPQ AI. AIDAL AIGII AKAPO AKBMS AKRWK AKYEP APXCP CITATION EJD FEDTE FGOYB G-2 HVGLF HZ~ H~9 MVM OHT OMK OZT PUQ R2- RIG UBW UHB VH1 X7M YYP YYQ ZGI ZHY ZKB ZY4 CGR CUY CVF ECM EFKBS EIF NPM 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c554t-eb00c0a2b85c5204bbb053f5fd4b4c6c85df2203ef79c10518cfcc37411cf3f23 |
| IEDL.DBID | IXB |
| ISSN | 0092-8674 1097-4172 |
| IngestDate | Thu Aug 21 14:14:33 EDT 2025 Fri Jul 11 05:14:37 EDT 2025 Fri Jul 11 04:42:11 EDT 2025 Mon Jul 21 05:59:34 EDT 2025 Tue Jul 01 02:17:11 EDT 2025 Thu Apr 24 23:12:46 EDT 2025 Fri Feb 23 02:38:37 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | COVID-19 original antigenic sin SARS-CoV-2 antibody immune memory boost Omicron B cells T cells mRNA vaccine |
| Language | English |
| License | Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c554t-eb00c0a2b85c5204bbb053f5fd4b4c6c85df2203ef79c10518cfcc37411cf3f23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally Lead contact |
| ORCID | 0000-0003-3133-0849 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8947944 |
| PMID | 35447072 |
| PQID | 2654294148 |
| PQPubID | 23479 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8947944 proquest_miscellaneous_2660983992 proquest_miscellaneous_2654294148 pubmed_primary_35447072 crossref_citationtrail_10_1016_j_cell_2022_03_038 crossref_primary_10_1016_j_cell_2022_03_038 elsevier_sciencedirect_doi_10_1016_j_cell_2022_03_038 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-28 |
| PublicationDateYYYYMMDD | 2022-04-28 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cell |
| PublicationTitleAlternate | Cell |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc Cell Press |
| Publisher_xml | – name: Elsevier Inc – name: Cell Press |
| References | Vanderheiden, Edara, Floyd, Kauffman, Mantus, Anderson, Rouphael, Edupuganti, Shi, Menachery (bib67) 2020; 131 Choi, Kim, Noh, Kim, Park, Jeong, Shin (bib10) 2022; 19 Pallesen, Wang, Corbett, Wrapp, Kirchdoerfer, Turner, Cottrell, Becker, Wang, Shi (bib50) 2017; 114 Tseng, Ackerson, Luo, Sy, Talarico, Tian, Bruxvoort, Tubert, Florea, Ku (bib65) 2022; 21 Halfmann, Iida, Iwatsuki-Horimoto, Maemura, Kiso, Scheaffer, Darling, Joshi, Loeber, Singh (bib32) 2022; 603 Francis (bib24) 1960; 104 Bar-On, Goldberg, Mandel, Bodenheimer, Freedman, Alroy-Preis, Ash, Huppert, Milo (bib5) 2021; 385 Edara, Pinsky, Suthar, Lai, Davis-Gardner, Floyd, Flowers, Wrammert, Hussaini, Ciric (bib21) 2021; 385 Sokal, Chappert, Barba-Spaeth, Roeser, Fourati, Azzaoui, Vandenberghe, Fernandez, Meola, Bouvier-Alias (bib61) 2021; 184 Schmidt, Muecksch, Weisblum, Da Silva, Bednarski, Cho, Wang, Gaebler, Caskey, Nussenzweig (bib58) 2022; 386 Teng, Nazzari, Choe, Liu, de Souza, Petrova, Tsybovsky, Wang, Zhang, Artamonov (bib64) 2021 Corbett, Werner, Connell, Gagne, Lai, Moliva, Flynn, Choi, Koch, Foulds (bib14) 2021; 22 Pilishvili, Gierke, Fleming-Dutra, Farrar, Mohr, Talan, Krishnadasan, Harland, Smithline, Hou (bib51) 2021; 385 Baden, El Sahly, Essink, Follmann, Neuzil, August, Clouting, Fortier, Deng, Han (bib76) 2021; 385 DiPiazza, Leist, Abiona, Moliva, Werner, Minai, Nagata, Bock, Phung, Schäfer (bib17) 2021; 54 Davies, Kassanjee, Rousseau, Morden, Johnson, Solomon, Hsiao, Hussey, Meintjes, Paleker (bib16) 2022 Wang, Zhou, Zhang, Yang, Schramm, Shi, Pegu, Oloniniyi, Henry, Darko (bib78) 2021; 373 Olia, Tsybovsky, Chen, Liu, Nazzari, Ou, Wang, Kong, Leung, Liu (bib48) 2021; 297 Sigal (bib60) 2022; 22 Vanderheiden, Thomas, Soung, Davis-Gardner, Floyd, Jin, Cowan, Pellegrini, Shi, Grakoui (bib68) 2021; 12 VanBlargan, Errico, Halfmann, Zost, Crowe, Purcell, Kawaoka, Corti, Fremont, Diamond (bib66) 2022; 28 Zhou, Teng, Olia, Cerutti, Gorman, Nazzari, Shi, Tsybovsky, Wang, Wang (bib75) 2020; 33 Accorsi, Britton, Fleming-Dutra, Smith, Shang, Derado, Miller, Schrag, Verani (bib2) 2022; 327 Köhler, Müller, Nara (bib41) 1994; 15 Wölfel, Corman, Guggemos, Seilmaier, Zange, Müller, Niemeyer, Jones, Vollmar, Rothe (bib71) 2020; 581 Hawman, Meade-White, Clancy, Archer, Hinkley, Leventhal, Rao, Stamper, Lewis, Rosenke (bib35) 2022 Donaldson, Kao, Foulds (bib18) 2019; 95 Goldberg, Mandel, Bar-On, Bodenheimer, Freedman, Haas, Milo, Alroy-Preis, Ash, Huppert (bib29) 2021; 385 Abdullah, Myers, Basu, Tintinger, Ueckermann, Mathebula, Ramlall, Spoor, de Villiers, Van der Walt (bib1) 2022; 116 Gostic, Ambrose, Worobey, Lloyd-Smith (bib30) 2016; 354 Katzelnick, Coello Escoto, McElvany, Chávez, Salje, Luo, Rodriguez-Barraquer, Jarman, Durbin, Diehl (bib39) 2018; 12 Bergwerk, Gonen, Lustig, Amit, Lipsitch, Cohen, Mandelboim, Levin, Rubin, Indenbaum (bib7) 2021; 385 Hassett, Benenato, Jacquinet, Lee, Woods, Yuzhakov, Himansu, Deterling, Geilich, Ketova (bib34) 2019; 15 Andrews, Stowe, Kirsebom, Toffa, Sachdeva, Gower, Ramsay, Lopez Bernal (bib3) 2022; 14 Wolter, Jassat, Walaza, Welch, Moultrie, Groome, Amoako, Everatt, Bhiman, Scheepers (bib72) 2022; 399 Kim, Lee, Yang, Kim, Kim, Chang (bib40) 2020; 181 Gagne, Corbett, Flynn, Foulds, Wagner, Andrew, Todd, Honeycutt, McCormick, Nurmukhambetova (bib26) 2022; 185 Viana, Moyo, Amoako, Tegally, Scheepers, Althaus, Anyaneji, Bester, Boni, Chand (bib69) 2022; 603 Corbett, Nason, Flach, Gagne, O’Connell, Johnston, Shah, Edara, Floyd, Lai (bib13) 2021; 373 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart, Perez, Pérez Marc, Moreira, Zerbini (bib54) 2020; 383 Hoffmann, Krüger, Schulz, Cossmann, Rocha, Kempf, Nehlmeier, Graichen, Moldenhauer, Winkler (bib36) 2022; 185 Corbett, Gagne, Wagner, O’Conell, Narpala, Flebbe, Andrew, Davis, Flynn (bib12) 2021; 374 Wrapp, Wang, Corbett, Goldsmith, Hsieh, Abiona, Graham, McLellan (bib74) 2020; 367 Shen, Tang, McDanal, Wagh, Fischer, Theiler, Yoon, Li, Haynes, Sanders (bib59) 2021; 29 Johnston, Poholek, DiToro, Yusuf, Eto, Barnett, Dent, Craft, Crotty (bib38) 2009; 325 Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine, Rajah, Planchais, Porrot, Robillard, Puech (bib53) 2021; 596 Gaebler, Wang, Lorenzi, Muecksch, Finkin, Tokuyama, Cho, Jankovic, Schaefer-Babajew, Oliveira (bib25) 2021; 591 Naldini, Blömer, Gage, Trono, Verma (bib46) 1996; 93 Edara, Manning, Ellis, Lai, Moore, Foster, Floyd, Davis-Gardner, Mantus, Nyhoff (bib19) 2022; 3 Francica, Flynn, Foulds, Noe, Werner, Moore, Gagne, Johnston, Tucker, Davis (bib23) 2021; 13 Lee, Sun, Wu, Lan, Wang, Liu, Tseng, Tsung, Chou, Kumari (bib42) 2022 Maslo, Friedland, Toubkin, Laubscher, Akaloo, Kama (bib43) 2022; 327 Grabowski, Kochańczyk, Lipniacki (bib31) 2022; 14 Wang, Zhang, Ge, Ren, Zhang, Lan, Ju, Su, Yu, Chen (bib79) 2021; 54 Willett, Grove, MacLean, Wilkie, Logan, Lorenzo, Furnon, Scott, Manali, Szemiel (bib70) 2022 Bentley, Kirby, Sharma, Kipar, Mega, Bramwell, Penrice-Randal, Prince, Brown, Zhou (bib6) 2021 Garcia-Beltran, St Denis, Hoelzemer, Lam, Nitido, Sheehan, Berrios, Ofoman, Chang, Hauser (bib27) 2022; 185 Meng, Abdullahi, Ferreira, Goonawardane, Saito, Kimura, Yamasoba, Gerber, Fatihi, Rathore (bib44) 2022; 603 Baden, El Sahly, Essink, Kotloff, Frey, Novak, Diemert, Spector, Rouphael, Creech (bib77) 2021; 384 Dagan, Barda, Kepten, Miron, Perchik, Katz, Hernán, Lipsitch, Reis, Balicer (bib15) 2021; 384 Richardson, Madzorera, Spencer, Manamela, van der Mescht, Lambson, Oosthuysen, Ayres, Makhado, Moyo-Gwete (bib55) 2022 Barda, Dagan, Cohen, Hernán, Lipsitch, Kohane, Reis, Balicer (bib4) 2021; 398 Rössler, Knabl, Laer, Kimpel (bib56) 2022 Hansen, Schelde, Moustsen-Helm, Emborg, Krause, Mølbak, Valentiner-Branth (bib33) 2021 Corbett, Flynn, Foulds, Francica, Boyoglu-Barnum, Werner, Flach, O'Connell, Bock, Minai (bib11) 2020; 383 Jackson, Anderson, Rouphael, Roberts, Makhene, Coler, McCullough, Chappell, Denison, Stevens (bib37) 2020; 383 Edara, Norwood, Floyd, Lai, Davis-Gardner, Hudson, Mantus, Nyhoff, Adelman, Fineman (bib20) 2021; 29 Cele, Jackson, Khoury, Khan, Moyo-Gwete, Tegally, San, Cromer, Scheepers, Amoako (bib8) 2022; 602 Nurieva, Chung, Martinez, Yang, Tanaka, Matskevitch, Wang, Dong (bib47) 2009; 325 Pajon, Doria-Rose, Shen, Schmidt, O'Dell, McDanal, Feng, Tong, Eaton, Maglinao (bib49) 2022; 386 Gilbert, Montefiori, McDermott, Fong, Benkeser, Deng, Zhou, Houchens, Martins, Jayashankar (bib28) 2021; 375 Choi, Koch, Wu, Chu, Ma, Hill, Nunna, Huang, Oestreicher, Colpitts (bib9) 2021; 27 Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco (bib52) 2020; 583 Worobey, Han, Rambaut (bib73) 2014; 111 Saunders, Lee, Parks, Martinez, Li, Chen, Edwards, Gobeil, Barr, Mansouri (bib57) 2021; 594 Muik, Lui, Wallisch, Bacher, Muhl, Reinholz, Ozhelvaci, Beckmann, Guimil Garcia, Poran (bib45) 2022; 375 Suryawanshi, Chen, Ma, Syed, Simoneau, Ciling, Khalid, Sreekumar, Chen, George (bib62) 2022 Tangye, Ferguson, Avery, Ma, Hodgkin (bib63) 2002; 169 Fonville, Wilks, James, Fox, Ventresca, Aban, Xue, Jones, Le, Pham (bib22) 2014; 346 Bergwerk (10.1016/j.cell.2022.03.038_bib7) 2021; 385 Donaldson (10.1016/j.cell.2022.03.038_bib18) 2019; 95 Wang (10.1016/j.cell.2022.03.038_bib78) 2021; 373 Bentley (10.1016/j.cell.2022.03.038_bib6) 2021 Naldini (10.1016/j.cell.2022.03.038_bib46) 1996; 93 Gilbert (10.1016/j.cell.2022.03.038_bib28) 2021; 375 Gostic (10.1016/j.cell.2022.03.038_bib30) 2016; 354 Tseng (10.1016/j.cell.2022.03.038_bib65) 2022; 21 Kim (10.1016/j.cell.2022.03.038_bib40) 2020; 181 Wang (10.1016/j.cell.2022.03.038_bib79) 2021; 54 Maslo (10.1016/j.cell.2022.03.038_bib43) 2022; 327 Baden (10.1016/j.cell.2022.03.038_bib76) 2021; 385 Choi (10.1016/j.cell.2022.03.038_bib10) 2022; 19 Vanderheiden (10.1016/j.cell.2022.03.038_bib67) 2020; 131 Wölfel (10.1016/j.cell.2022.03.038_bib71) 2020; 581 VanBlargan (10.1016/j.cell.2022.03.038_bib66) 2022; 28 Hawman (10.1016/j.cell.2022.03.038_bib35) 2022 Suryawanshi (10.1016/j.cell.2022.03.038_bib62) 2022 Corbett (10.1016/j.cell.2022.03.038_bib13) 2021; 373 Dagan (10.1016/j.cell.2022.03.038_bib15) 2021; 384 Muik (10.1016/j.cell.2022.03.038_bib45) 2022; 375 Gagne (10.1016/j.cell.2022.03.038_bib26) 2022; 185 DiPiazza (10.1016/j.cell.2022.03.038_bib17) 2021; 54 Vanderheiden (10.1016/j.cell.2022.03.038_bib68) 2021; 12 Hansen (10.1016/j.cell.2022.03.038_bib33) 2021 Pinto (10.1016/j.cell.2022.03.038_bib52) 2020; 583 Fonville (10.1016/j.cell.2022.03.038_bib22) 2014; 346 Pajon (10.1016/j.cell.2022.03.038_bib49) 2022; 386 Cele (10.1016/j.cell.2022.03.038_bib8) 2022; 602 Viana (10.1016/j.cell.2022.03.038_bib69) 2022; 603 Corbett (10.1016/j.cell.2022.03.038_bib12) 2021; 374 Pallesen (10.1016/j.cell.2022.03.038_bib50) 2017; 114 Katzelnick (10.1016/j.cell.2022.03.038_bib39) 2018; 12 Garcia-Beltran (10.1016/j.cell.2022.03.038_bib27) 2022; 185 Gaebler (10.1016/j.cell.2022.03.038_bib25) 2021; 591 Hoffmann (10.1016/j.cell.2022.03.038_bib36) 2022; 185 Rössler (10.1016/j.cell.2022.03.038_bib56) 2022 Davies (10.1016/j.cell.2022.03.038_bib16) 2022 Polack (10.1016/j.cell.2022.03.038_bib54) 2020; 383 Accorsi (10.1016/j.cell.2022.03.038_bib2) 2022; 327 Lee (10.1016/j.cell.2022.03.038_bib42) 2022 Abdullah (10.1016/j.cell.2022.03.038_bib1) 2022; 116 Schmidt (10.1016/j.cell.2022.03.038_bib58) 2022; 386 Bar-On (10.1016/j.cell.2022.03.038_bib5) 2021; 385 Corbett (10.1016/j.cell.2022.03.038_bib14) 2021; 22 Choi (10.1016/j.cell.2022.03.038_bib9) 2021; 27 Meng (10.1016/j.cell.2022.03.038_bib44) 2022; 603 Goldberg (10.1016/j.cell.2022.03.038_bib29) 2021; 385 Nurieva (10.1016/j.cell.2022.03.038_bib47) 2009; 325 Planas (10.1016/j.cell.2022.03.038_bib53) 2021; 596 Wolter (10.1016/j.cell.2022.03.038_bib72) 2022; 399 Grabowski (10.1016/j.cell.2022.03.038_bib31) 2022; 14 Francis (10.1016/j.cell.2022.03.038_bib24) 1960; 104 Edara (10.1016/j.cell.2022.03.038_bib19) 2022; 3 Edara (10.1016/j.cell.2022.03.038_bib21) 2021; 385 Tangye (10.1016/j.cell.2022.03.038_bib63) 2002; 169 Wrapp (10.1016/j.cell.2022.03.038_bib74) 2020; 367 Francica (10.1016/j.cell.2022.03.038_bib23) 2021; 13 Edara (10.1016/j.cell.2022.03.038_bib20) 2021; 29 Johnston (10.1016/j.cell.2022.03.038_bib38) 2009; 325 Sigal (10.1016/j.cell.2022.03.038_bib60) 2022; 22 Willett (10.1016/j.cell.2022.03.038_bib70) 2022 Corbett (10.1016/j.cell.2022.03.038_bib11) 2020; 383 Barda (10.1016/j.cell.2022.03.038_bib4) 2021; 398 Hassett (10.1016/j.cell.2022.03.038_bib34) 2019; 15 Worobey (10.1016/j.cell.2022.03.038_bib73) 2014; 111 Richardson (10.1016/j.cell.2022.03.038_bib55) 2022 Teng (10.1016/j.cell.2022.03.038_bib64) 2021 Baden (10.1016/j.cell.2022.03.038_bib77) 2021; 384 Shen (10.1016/j.cell.2022.03.038_bib59) 2021; 29 Pilishvili (10.1016/j.cell.2022.03.038_bib51) 2021; 385 Halfmann (10.1016/j.cell.2022.03.038_bib32) 2022; 603 Saunders (10.1016/j.cell.2022.03.038_bib57) 2021; 594 Jackson (10.1016/j.cell.2022.03.038_bib37) 2020; 383 Köhler (10.1016/j.cell.2022.03.038_bib41) 1994; 15 Andrews (10.1016/j.cell.2022.03.038_bib3) 2022; 14 Sokal (10.1016/j.cell.2022.03.038_bib61) 2021; 184 Olia (10.1016/j.cell.2022.03.038_bib48) 2021; 297 Zhou (10.1016/j.cell.2022.03.038_bib75) 2020; 33 |
| References_xml | – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bib54 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. – volume: 383 start-page: 1920 year: 2020 end-page: 1931 ident: bib37 article-title: An mRNA vaccine against SARS-CoV-2 - preliminary Report publication-title: N. Engl. J. Med. – year: 2022 ident: bib55 article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals publication-title: Preprint at medRxiv – volume: 185 start-page: 113 year: 2022 end-page: 130.e15 ident: bib26 article-title: Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung publication-title: Cell – volume: 383 start-page: 1544 year: 2020 end-page: 1555 ident: bib11 article-title: Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: N. Engl. J. Med. – year: 2022 ident: bib16 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: Preprint at medRxiv – volume: 346 start-page: 996 year: 2014 end-page: 1000 ident: bib22 article-title: Antibody landscapes after influenza virus infection or vaccination publication-title: Science – volume: 111 start-page: 8107 year: 2014 end-page: 8112 ident: bib73 article-title: Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus publication-title: Proc. Natl. Acad. Sci. USA – volume: 385 start-page: 2485 year: 2021 end-page: 2487 ident: bib76 article-title: Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge publication-title: N Engl J Med – volume: 603 start-page: 706 year: 2022 end-page: 714 ident: bib44 article-title: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity publication-title: Nature – volume: 603 start-page: 679 year: 2022 end-page: 686 ident: bib69 article-title: Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa publication-title: Nature – volume: 33 start-page: 108322 year: 2020 ident: bib75 article-title: Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike Molecular Probes publication-title: Cell Rep. – year: 2022 ident: bib62 article-title: Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination publication-title: Preprint at medRxiv – volume: 95 start-page: 261 year: 2019 end-page: 263 ident: bib18 article-title: OMIP-052: an 18-color panel for measuring Th1, Th2, Th17, and Tfh responses in rhesus macaques publication-title: Cytometry A – volume: 22 start-page: 1306 year: 2021 end-page: 1315 ident: bib14 article-title: mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates publication-title: Nat. Immunol. – year: 2021 ident: bib6 article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 publication-title: Preprint at bioRxiv – volume: 12 start-page: e0006862 year: 2018 ident: bib39 article-title: Viridot: an automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus publication-title: PLoS Negl. Trop. Dis. – volume: 327 start-page: 639 year: 2022 end-page: 651 ident: bib2 article-title: Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and Delta variants publication-title: JAMA – volume: 297 start-page: 101127 year: 2021 ident: bib48 article-title: SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity publication-title: J. Biol. Chem. – volume: 28 start-page: 490 year: 2022 end-page: 495 ident: bib66 article-title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies publication-title: Nat. Med. – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: bib77 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med – volume: 131 start-page: e116 year: 2020 ident: bib67 article-title: Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies publication-title: Curr. Protoc. Immunol. – volume: 374 start-page: eabl8912 year: 2021 ident: bib12 article-title: Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates publication-title: Science – volume: 384 start-page: 1412 year: 2021 end-page: 1423 ident: bib15 article-title: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting publication-title: N. Engl. J. Med. – volume: 12 start-page: e0274921 year: 2021 ident: bib68 article-title: CCR2 signaling restricts SARS-CoV-2 infection publication-title: mBio – volume: 385 start-page: 2421 year: 2021 end-page: 2430 ident: bib5 article-title: Protection against Covid-19 by BNT162b2 booster across age groups publication-title: N. Engl. J. Med. – volume: 21 start-page: 2022 year: 2022 ident: bib65 article-title: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants publication-title: Nat. Med. Published online February – year: 2022 ident: bib35 article-title: Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine publication-title: Preprint at bioRxiv – year: 2021 ident: bib64 article-title: Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron publication-title: Preprint at bioRxiv – volume: 29 start-page: 529 year: 2021 end-page: 539.e3 ident: bib59 article-title: SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines publication-title: Cell Host Microbe – volume: 385 start-page: 664 year: 2021 end-page: 666 ident: bib21 article-title: Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 Variants publication-title: N. Engl. J. Med. – volume: 3 start-page: 100529 year: 2022 ident: bib19 article-title: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant publication-title: Cell Rep. Med. – volume: 15 start-page: 1 year: 2019 end-page: 11 ident: bib34 article-title: Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines publication-title: Mol. Ther. Nucleic Acids – volume: 54 start-page: 1869 year: 2021 end-page: 1882.e6 ident: bib17 article-title: COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge publication-title: Immunity – volume: 385 start-page: e85 year: 2021 ident: bib29 article-title: Waning immunity after the BNT162b2 vaccine in Israel publication-title: N. Engl. J. Med. – volume: 325 start-page: 1001 year: 2009 end-page: 1005 ident: bib47 article-title: Bcl6 mediates the development of T follicular helper cells publication-title: Science – volume: 367 start-page: 1260 year: 2020 end-page: 1263 ident: bib74 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science – year: 2022 ident: bib56 article-title: Neutralization profile of Omicron variant convalescent individuals publication-title: Preprint at medRxiv – volume: 19 start-page: 447 year: 2022 end-page: 448 ident: bib10 article-title: T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant publication-title: Cell. Mol. Immunol. – volume: 581 start-page: 465 year: 2020 end-page: 469 ident: bib71 article-title: Virological assessment of hospitalized patients with COVID-2019 publication-title: Nature – volume: 116 start-page: 38 year: 2022 end-page: 42 ident: bib1 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa publication-title: Int. J. Infect. Dis. – volume: 375 start-page: eabn7591 year: 2022 ident: bib45 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science – volume: 373 year: 2021 ident: bib78 article-title: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants publication-title: Science – volume: 385 start-page: e90 year: 2021 ident: bib51 article-title: Effectiveness of mRNA Covid-19 vaccine among U.S. Health care personnel publication-title: N. Engl. J. Med. – volume: 185 start-page: 447 year: 2022 end-page: 456 ident: bib36 article-title: The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic publication-title: Cell – year: 2021 ident: bib33 article-title: Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study publication-title: Preprint at medRxiv – volume: 325 start-page: 1006 year: 2009 end-page: 1010 ident: bib38 article-title: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation publication-title: Science – volume: 14 start-page: 2022 year: 2022 ident: bib3 article-title: Effectiveness of COVID-19 booster vaccines against covid-19-related symptoms, hospitalisation and death in England publication-title: Nat. Med. Published online January – volume: 602 start-page: 654 year: 2022 end-page: 656 ident: bib8 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature – year: 2022 ident: bib42 article-title: Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants publication-title: Preprint at bioRxiv – volume: 386 start-page: 599 year: 2022 end-page: 601 ident: bib58 article-title: Plasma neutralization of the SARS-CoV-2 omicron variant publication-title: N. Engl. J. Med. – volume: 13 start-page: eabi4547 year: 2021 ident: bib23 article-title: Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates publication-title: Sci. Transl. Med. – volume: 22 start-page: 69 year: 2022 end-page: 71 ident: bib60 article-title: Milder disease with Omicron: is it the virus or the pre-existing immunity? publication-title: Nat. Rev. Immunol. – volume: 591 start-page: 639 year: 2021 end-page: 644 ident: bib25 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature – volume: 594 start-page: 553 year: 2021 end-page: 559 ident: bib57 article-title: Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses publication-title: Nature – volume: 181 start-page: 914 year: 2020 end-page: 921.e10 ident: bib40 article-title: The architecture of SARS-CoV-2 transcriptome publication-title: Cell – volume: 169 start-page: 4298 year: 2002 end-page: 4306 ident: bib63 article-title: Isotype switching by human B cells is division-associated and regulated by cytokines publication-title: J. Immunol. – volume: 398 start-page: 2093 year: 2021 end-page: 2100 ident: bib4 article-title: Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study publication-title: Lancet – volume: 14 start-page: 294 year: 2022 ident: bib31 article-title: The spread of SARS-CoV-2 variant omicron with a doubling time of 2.0–3.3 days can be explained by immune evasion publication-title: Viruses – volume: 385 start-page: 1474 year: 2021 end-page: 1484 ident: bib7 article-title: Covid-19 breakthrough infections in vaccinated health care workers publication-title: N. Engl. J. Med. – volume: 29 start-page: 516 year: 2021 end-page: 521.e3 ident: bib20 article-title: Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant publication-title: Cell Host Microbe – volume: 114 start-page: E7348 year: 2017 end-page: E7357 ident: bib50 article-title: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen publication-title: Proc. Natl. Acad. Sci. USA – volume: 596 start-page: 276 year: 2021 end-page: 280 ident: bib53 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature – volume: 373 start-page: eabj0299 year: 2021 ident: bib13 article-title: Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: Science – year: 2022 ident: bib70 article-title: The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism publication-title: Preprint at medRxiv – volume: 27 start-page: 2025 year: 2021 end-page: 2031 ident: bib9 article-title: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis publication-title: Nat. Med. – volume: 93 start-page: 11382 year: 1996 end-page: 11388 ident: bib46 article-title: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector publication-title: Proc. Natl. Acad. Sci. USA – volume: 603 start-page: 687 year: 2022 end-page: 692 ident: bib32 article-title: SARS-CoV-2 Omicron Virus Causes Attenuated Disease in Mice and Hamsters publication-title: Nature – volume: 583 start-page: 290 year: 2020 end-page: 295 ident: bib52 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature – volume: 15 start-page: 475 year: 1994 end-page: 478 ident: bib41 article-title: Deceptive imprinting in the immune response against HIV-1 publication-title: Immunol. Today – volume: 184 start-page: 1201 year: 2021 end-page: 1213.e14 ident: bib61 article-title: Maturation and persistence of the anti-SARS-CoV-2 memory B cell response publication-title: Cell – volume: 386 start-page: 1088 year: 2022 end-page: 1091 ident: bib49 article-title: SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination publication-title: N. Engl. J. Med. – volume: 354 start-page: 722 year: 2016 end-page: 726 ident: bib30 article-title: Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting publication-title: Science – volume: 54 start-page: 1611 year: 2021 end-page: 1621.e5 ident: bib79 article-title: Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species publication-title: Immunity – volume: 399 start-page: 437 year: 2022 end-page: 446 ident: bib72 article-title: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study publication-title: Lancet – volume: 375 start-page: 43 year: 2021 end-page: 50 ident: bib28 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science – volume: 185 start-page: 457 year: 2022 end-page: 466.e4 ident: bib27 article-title: mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant publication-title: Cell – volume: 104 start-page: 572 year: 1960 end-page: 578 ident: bib24 article-title: On the doctrine of original antigenic sin publication-title: Proc. Am. Philos. Soc. – volume: 327 start-page: 583 year: 2022 end-page: 584 ident: bib43 article-title: Characteristics and outcomes of hospitalized patients in South Africa During the COVID-19 omicron wave compared With previous waves publication-title: JAMA – volume: 27 start-page: 2025 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib9 article-title: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis publication-title: Nat. Med. doi: 10.1038/s41591-021-01527-y – volume: 184 start-page: 1201 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib61 article-title: Maturation and persistence of the anti-SARS-CoV-2 memory B cell response publication-title: Cell doi: 10.1016/j.cell.2021.01.050 – volume: 29 start-page: 529 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib59 article-title: SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.002 – volume: 603 start-page: 679 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib69 article-title: Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa publication-title: Nature doi: 10.1038/s41586-022-04411-y – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib16 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: Preprint at medRxiv – volume: 385 start-page: 2485 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib76 article-title: Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge publication-title: N Engl J Med doi: 10.1056/NEJMc2115597 – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib62 article-title: Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination publication-title: Preprint at medRxiv – volume: 131 start-page: e116 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib67 article-title: Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies publication-title: Curr. Protoc. Immunol. doi: 10.1002/cpim.116 – volume: 385 start-page: 1474 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib7 article-title: Covid-19 breakthrough infections in vaccinated health care workers publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2109072 – volume: 297 start-page: 101127 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib48 article-title: SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity publication-title: J. Biol. Chem. doi: 10.1016/j.jbc.2021.101127 – volume: 602 start-page: 654 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib8 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature doi: 10.1038/s41586-021-04387-1 – volume: 95 start-page: 261 year: 2019 ident: 10.1016/j.cell.2022.03.038_bib18 article-title: OMIP-052: an 18-color panel for measuring Th1, Th2, Th17, and Tfh responses in rhesus macaques publication-title: Cytometry A doi: 10.1002/cyto.a.23670 – volume: 385 start-page: e90 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib51 article-title: Effectiveness of mRNA Covid-19 vaccine among U.S. Health care personnel publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2106599 – volume: 375 start-page: eabn7591 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib45 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science doi: 10.1126/science.abn7591 – volume: 346 start-page: 996 year: 2014 ident: 10.1016/j.cell.2022.03.038_bib22 article-title: Antibody landscapes after influenza virus infection or vaccination publication-title: Science doi: 10.1126/science.1256427 – volume: 325 start-page: 1006 year: 2009 ident: 10.1016/j.cell.2022.03.038_bib38 article-title: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation publication-title: Science doi: 10.1126/science.1175870 – volume: 185 start-page: 457 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib27 article-title: mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant publication-title: Cell doi: 10.1016/j.cell.2021.12.033 – volume: 386 start-page: 1088 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib49 article-title: SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2119912 – volume: 373 start-page: eabj0299 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib13 article-title: Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: Science doi: 10.1126/science.abj0299 – volume: 596 start-page: 276 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib53 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-03777-9 – volume: 12 start-page: e0006862 year: 2018 ident: 10.1016/j.cell.2022.03.038_bib39 article-title: Viridot: an automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus publication-title: PLoS Negl. Trop. Dis. doi: 10.1371/journal.pntd.0006862 – volume: 399 start-page: 437 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib72 article-title: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study publication-title: Lancet doi: 10.1016/S0140-6736(22)00017-4 – volume: 375 start-page: 43 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib28 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science doi: 10.1126/science.abm3425 – volume: 181 start-page: 914 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib40 article-title: The architecture of SARS-CoV-2 transcriptome publication-title: Cell doi: 10.1016/j.cell.2020.04.011 – volume: 374 start-page: eabl8912 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib12 article-title: Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates publication-title: Science doi: 10.1126/science.abl8912 – volume: 385 start-page: e85 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib29 article-title: Waning immunity after the BNT162b2 vaccine in Israel publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2114228 – volume: 22 start-page: 1306 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib14 article-title: mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates publication-title: Nat. Immunol. doi: 10.1038/s41590-021-01021-0 – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib56 article-title: Neutralization profile of Omicron variant convalescent individuals publication-title: Preprint at medRxiv – volume: 325 start-page: 1001 year: 2009 ident: 10.1016/j.cell.2022.03.038_bib47 article-title: Bcl6 mediates the development of T follicular helper cells publication-title: Science doi: 10.1126/science.1176676 – volume: 21 start-page: 2022 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib65 article-title: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants publication-title: Nat. Med. Published online February – volume: 581 start-page: 465 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib71 article-title: Virological assessment of hospitalized patients with COVID-2019 publication-title: Nature doi: 10.1038/s41586-020-2196-x – volume: 185 start-page: 113 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib26 article-title: Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung publication-title: Cell doi: 10.1016/j.cell.2021.12.002 – volume: 383 start-page: 1920 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib37 article-title: An mRNA vaccine against SARS-CoV-2 - preliminary Report publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022483 – volume: 33 start-page: 108322 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib75 article-title: Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike Molecular Probes publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108322 – volume: 354 start-page: 722 year: 2016 ident: 10.1016/j.cell.2022.03.038_bib30 article-title: Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting publication-title: Science doi: 10.1126/science.aag1322 – volume: 14 start-page: 2022 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib3 article-title: Effectiveness of COVID-19 booster vaccines against covid-19-related symptoms, hospitalisation and death in England publication-title: Nat. Med. Published online January – volume: 54 start-page: 1611 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib79 article-title: Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species publication-title: Immunity doi: 10.1016/j.immuni.2021.06.003 – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib70 article-title: The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism publication-title: Preprint at medRxiv – volume: 583 start-page: 290 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib52 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature doi: 10.1038/s41586-020-2349-y – volume: 114 start-page: E7348 year: 2017 ident: 10.1016/j.cell.2022.03.038_bib50 article-title: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1707304114 – volume: 327 start-page: 639 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib2 article-title: Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and Delta variants publication-title: JAMA doi: 10.1001/jama.2022.0470 – year: 2021 ident: 10.1016/j.cell.2022.03.038_bib33 article-title: Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study publication-title: Preprint at medRxiv – volume: 104 start-page: 572 year: 1960 ident: 10.1016/j.cell.2022.03.038_bib24 article-title: On the doctrine of original antigenic sin publication-title: Proc. Am. Philos. Soc. – volume: 22 start-page: 69 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib60 article-title: Milder disease with Omicron: is it the virus or the pre-existing immunity? publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-022-00678-4 – volume: 398 start-page: 2093 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib4 article-title: Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study publication-title: Lancet doi: 10.1016/S0140-6736(21)02249-2 – volume: 54 start-page: 1869 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib17 article-title: COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge publication-title: Immunity doi: 10.1016/j.immuni.2021.06.018 – volume: 14 start-page: 294 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib31 article-title: The spread of SARS-CoV-2 variant omicron with a doubling time of 2.0–3.3 days can be explained by immune evasion publication-title: Viruses doi: 10.3390/v14020294 – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib55 article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals publication-title: Preprint at medRxiv – volume: 13 start-page: eabi4547 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib23 article-title: Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abi4547 – volume: 385 start-page: 2421 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib5 article-title: Protection against Covid-19 by BNT162b2 booster across age groups publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2115926 – year: 2021 ident: 10.1016/j.cell.2022.03.038_bib64 article-title: Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron publication-title: Preprint at bioRxiv – volume: 385 start-page: 664 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib21 article-title: Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 Variants publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2107799 – volume: 383 start-page: 1544 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib11 article-title: Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2024671 – volume: 373 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib78 article-title: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants publication-title: Science doi: 10.1126/science.abh1766 – volume: 19 start-page: 447 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib10 article-title: T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant publication-title: Cell. Mol. Immunol. doi: 10.1038/s41423-022-00838-5 – volume: 93 start-page: 11382 year: 1996 ident: 10.1016/j.cell.2022.03.038_bib46 article-title: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.93.21.11382 – volume: 594 start-page: 553 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib57 article-title: Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses publication-title: Nature doi: 10.1038/s41586-021-03594-0 – volume: 15 start-page: 1 year: 2019 ident: 10.1016/j.cell.2022.03.038_bib34 article-title: Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines publication-title: Mol. Ther. Nucleic Acids doi: 10.1016/j.omtn.2019.01.013 – volume: 3 start-page: 100529 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib19 article-title: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2022.100529 – volume: 603 start-page: 706 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib44 article-title: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity publication-title: Nature doi: 10.1038/s41586-022-04474-x – volume: 185 start-page: 447 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib36 article-title: The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic publication-title: Cell doi: 10.1016/j.cell.2021.12.032 – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib54 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – volume: 28 start-page: 490 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib66 article-title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies publication-title: Nat. Med. doi: 10.1038/s41591-021-01678-y – volume: 367 start-page: 1260 year: 2020 ident: 10.1016/j.cell.2022.03.038_bib74 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science doi: 10.1126/science.abb2507 – volume: 386 start-page: 599 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib58 article-title: Plasma neutralization of the SARS-CoV-2 omicron variant publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2119641 – volume: 15 start-page: 475 year: 1994 ident: 10.1016/j.cell.2022.03.038_bib41 article-title: Deceptive imprinting in the immune response against HIV-1 publication-title: Immunol. Today doi: 10.1016/0167-5699(94)90192-9 – volume: 12 start-page: e0274921 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib68 article-title: CCR2 signaling restricts SARS-CoV-2 infection publication-title: mBio doi: 10.1128/mBio.02749-21 – volume: 116 start-page: 38 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib1 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2021.12.357 – volume: 29 start-page: 516 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib20 article-title: Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.009 – volume: 591 start-page: 639 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib25 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03207-w – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib35 article-title: Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine publication-title: Preprint at bioRxiv – year: 2022 ident: 10.1016/j.cell.2022.03.038_bib42 article-title: Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants publication-title: Preprint at bioRxiv – volume: 384 start-page: 1412 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib15 article-title: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101765 – volume: 111 start-page: 8107 year: 2014 ident: 10.1016/j.cell.2022.03.038_bib73 article-title: Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1324197111 – volume: 327 start-page: 583 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib43 article-title: Characteristics and outcomes of hospitalized patients in South Africa During the COVID-19 omicron wave compared With previous waves publication-title: JAMA doi: 10.1001/jama.2021.24868 – year: 2021 ident: 10.1016/j.cell.2022.03.038_bib6 article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 publication-title: Preprint at bioRxiv – volume: 384 start-page: 403 year: 2021 ident: 10.1016/j.cell.2022.03.038_bib77 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – volume: 603 start-page: 687 year: 2022 ident: 10.1016/j.cell.2022.03.038_bib32 article-title: SARS-CoV-2 Omicron Virus Causes Attenuated Disease in Mice and Hamsters publication-title: Nature doi: 10.1038/s41586-022-04441-6 – volume: 169 start-page: 4298 year: 2002 ident: 10.1016/j.cell.2022.03.038_bib63 article-title: Isotype switching by human B cells is division-associated and regulated by cytokines publication-title: J. Immunol. doi: 10.4049/jimmunol.169.8.4298 |
| SSID | ssj0008555 |
| Score | 2.6636312 |
| Snippet | SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1556 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Animals Antibodies, Neutralizing Antibodies, Viral antibody B cells B-lymphocytes boost COVID-19 COVID-19 - prevention & control immune memory immunity immunization Macaca mRNA vaccine neutralization Omicron original antigenic sin RNA, Messenger SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 T cells virus replication |
| Title | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron |
| URI | https://dx.doi.org/10.1016/j.cell.2022.03.038 https://www.ncbi.nlm.nih.gov/pubmed/35447072 https://www.proquest.com/docview/2654294148 https://www.proquest.com/docview/2660983992 https://pubmed.ncbi.nlm.nih.gov/PMC8947944 |
| Volume | 185 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhEOil9N3tI0yht8bE1sOWj0lICIWmUBrYm5FkmbpktWHtLW1_Q390Z2x5ybZlD8W-yBph6zGjb-R5MPY287k2hswqCuESKYxNbJEhkKu54wiQbT3E7vxwlV9ey_dzNd9jZ5MvDJlVRtk_yvRBWscnx3E0j2_blnx8S65zVO3IvkprcuITUg9OfPPTjTTWSo1ZDErkfKSOjjOjjRcdjqOOyPkQ6JR8VP69Of0NPv-0obyzKV08YPcjmoST8YMfsj0fHrGDMb_kj8fs1-LT1UmSIXaA5QqGwscFWeAFQHDd9dAG-GacawMizhoWxhl6P_ib1rV9B127aFHzhVOgLoD_jqKDTteOIPj1cETyE3c-WI12tr47AhNqiKEfkA7IeQXiK5-w64vzz2eXSUy_kDjEGH1CWYVcarjVyimeSmstcmyjmlpa6XKnVd3g2AvfFKVDmJZp1zgnEKJkrhENF0_ZflgG_5yBciYtmgwvnVJ6E1Mj39eknWrljRUzlk3jXrkYm5xSZNxUkxHa14o6WtFcVanAW8_Yu02b2zEyx05qNU1ntbW-Ktw6drZ7M819hYxH1Sb45bqr-JDqS6I6uYsmT0tNsX9n7Nm4XjbfKpSURVpgTbG1kjYEFPh7uya0X4YA4LqkvADyxX_26SW7RyX6J8b1K7bfr9b-NUKr3h4OvPMbSx0jmw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIQQviPFv5a-R4IlFS5w4cR542ICpZVuR0Cb1zdiOI4JWd2pSYHwGvg1fcHeJU1FAfUCa2pfWThP77Lvfub-7I-RFZFOhFNIqstgESax0oLMIgFzBDAOArIs2d-fxOB2eJu8nfLJBfvWxMEir9Lq_0-mttvbf7PrZ3D2vKozxzZlIwbVDfpUQuWdWHtqLb-C31a9Hb0HILxk7eHfyZhj40gKBAfvZBFgxx4SKacENZ2GitYbVWPKySHRiUiN4UcLvxrbMcgMQJBKmNCYG8xuZMi4x2wHo_WuAPjLUBqPJ_lL9C867sgk5qBp4PB-p05HK8DQenFLG2syqGBTzb2v4N9r9k7T5mxU8uE1uefhK97oZ2iIb1t0h17uClhd3yc_px_FeEAFYobM5bT98mCLlz1FA83VDK0e_KmMqBxC3oFNlFN6f2rPKVE1N62pagatN9ykOgdrvoKvwOG-HOrtoz2R-gKml847Ya-sdqlxBfa4J6EcxWob6W94jp1cilPtk082c3SaUGxVmZQQvEWI9FVWAoinQHRbcKh0PSNTPuzQ-GTrW5DiTPevti8SBSpSVDGN4iwF5tbzmvEsFsrY378UpVxa0BFu19rrnvewl7HRsVs7OFrVkbW2xBPzXdX3SMBeYbHhAHnTrZfmsMU-SLMygJVtZScsOmGl8tcVVn9uM4yLHQgTJw_8c0zNyY3hyfCSPRuPDR-QmtuAfckw8JpvNfGGfAK5r9NN2H1Hy6ao37iXWWmFv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=mRNA-1273+or+mRNA-Omicron+boost+in+vaccinated+macaques+elicits+similar+B+cell+expansion%2C+neutralizing+responses%2C+and+protection+from+Omicron&rft.jtitle=Cell&rft.au=Gagne%2C+Matthew&rft.au=Moliva%2C+Juan+I.&rft.au=Foulds%2C+Kathryn+E.&rft.au=Andrew%2C+Shayne+F.&rft.date=2022-04-28&rft.issn=0092-8674&rft.volume=185&rft.issue=9&rft.spage=1556&rft.epage=1571.e18&rft_id=info:doi/10.1016%2Fj.cell.2022.03.038&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_cell_2022_03_038 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0092-8674&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0092-8674&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0092-8674&client=summon |